• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Biomol Struct Dyn. Potential Inhibitors of Coronavirus 3-Chymotrypsin-Like Protease (3CLpro): An in silico screening of Alkaloids and Terpenoids fr

tetano

Editor, Senior Moderator
J Biomol Struct Dyn. 2020 May 5:1-19. doi: 10.1080/07391102.2020.1764868. [Epub ahead of print]
Potential Inhibitors of Coronavirus 3-Chymotrypsin-Like Protease (3CL[SUP]pro[/SUP]): An in silico screening of Alkaloids and Terpenoids from African medicinal plants.


Gyebi GA[SUP]1[/SUP], Ogunro OB[SUP]2[/SUP], Adegunloye AP[SUP]3[/SUP], Ogunyemi OM[SUP]1[/SUP], Afolabi SO[SUP]4[/SUP].

Author information




Abstract

The novel coronavirus disease 2019 (COVID-19) caused by SARS-COV-2 has raised myriad of global concerns. There is currently no FDA approved antiviral strategy to alleviate the disease burden. The conserved 3-chymotrypsin-like protease (3CL[SUP]pro[/SUP]), which controls coronavirus replication is a promising drug target for combating the coronavirus infection. This study screens some African plants derived alkaloids and terpenoids as potential inhibitors of coronavirus 3CL[SUP]pro[/SUP] using in silico approach.Bioactive alkaloids (62) and terpenoids (100) of plants native to Africa were docked to the 3CL[SUP]pro[/SUP] of the novel SARS-CoV-2. The top twenty alkaloids and terpenoids with high binding affinities to the SARS-CoV-2 3CL[SUP]pro[/SUP] were further docked to the 3CL[SUP]pro[/SUP] of SARS-CoV and MERS-CoV. The docking scores were compared with 3CL[SUP]pro[/SUP]-referenced inhibitors (Lopinavir and Ritonavir). The top docked compounds were further subjected to ADEM/Tox and Lipinski filtering analyses for drug-likeness prediction analysis.This ligand-protein interaction study revealed that more than half of the top twenty alkaloids and terpenoids interacted favourably with the coronaviruses 3CL[SUP]pro[/SUP], and had binding affinities that surpassed that of lopinavir and ritonavir. Also, a highly defined hit-list of seven compounds (10-Hydroxyusambarensine, Cryptoquindoline, 6-Oxoisoiguesterin, 22-Hydroxyhopan-3-one, Cryptospirolepine, Isoiguesterin and 20-Epibryonolic acid) were identified. Furthermore, four non-toxic, druggable plant derived alkaloids (10-Hydroxyusambarensine, and Cryptoquindoline) and terpenoids (6-Oxoisoiguesterin and 22-Hydroxyhopan-3-one), that bind to the receptor-binding site and catalytic dyad of SARS-CoV-2 3CL[SUP]pro[/SUP] were identified from the predictive ADME/tox and Lipinski filter analysis. However, further experimental analyses are required for developing these possible leads into natural anti-COVID-19 therapeutic agents for combating the pandemic.



KEYWORDS:

COVID-19; Coronavirus 3CLpro; Molecular docking; Natural product; SARS-CoV-2


PMID:32367767DOI:10.1080/07391102.2020.1764868
 
Back
Top Bottom